Table 1 Baseline characteristics of the non-CI-AKI and CI-AKI groups

Male (n, %)

27 (52.9%)

280 (57.1%)

0.564

Age (years) P₅₀ (P₂₅–P₇₅)

72 (62–76)

63 (56–71)

0.001

SBP (mmHg) P₅₀ (P₂₅–P₇₅)

136 (122–155)

134 (122–146)

0.222

DBP (mmHg) P₅₀ (P₂₅–P₇₅)

78 (69–84)

76 (69–84)

0.799

BMI (kg/m²) P₅₀ (P₂₅–P₇₅)

25 (23–27)

25 (23–27)

0.545

Hypertension (n, %)

47 (92.2%)

348 (71.0%)

0.005

Atrial fibrillation (n, %)

6 (11.8%)

33 (6.7%)

0.186

Acute myocardial infarction (n, %)

7 (13.7%)

38 (7.8%)

0.142

Coronary angiology

 < 0.001

Lesion vessels (N ≤ 2)

26 (51.0%)

363 (73.9%)

Lesion vessels (N ≥ 3)

25 (49.0%)

128 (26.1%)

Dose of contrast agent P₅₀ (P₂₅–P₇₅) (ml)

35 (25–100)

30 (20–60)

0.069

Hydration (n, %)

51 (100%)

489 (99.8%)

0.747

In-hospital medication

 Aspirin (n, %)

45 (85.2%)

419 (85.5%)

0.596

 ACEI/ARB (n, %)

30 (58.8%)

232 (47.4%)

0.119

 β-blocker (n, %)

39 (76.5%)

301 (61.4%)

0.034

 Statin (n, %)

48 (94.1%)

456 (93.1%)

0.776

 Digoxin (n, %)

7 (13.7%)

14 (2.9%)

0.000

Laboratory test

 Hb P₅₀ (P₂₅–P₇₅)

125 (112–137)

138 (128–150)

0.000

 PLT P₅₀ (P₂₅–P₇₅)

188 (160–244)

201 (166–236)

0.613

 TB P₅₀ (P₂₅–P₇₅)

10.5 (7.6–15.5)

11.2 (9.0–14.1)

0.613

 BUN P₅₀ (P₂₅–P₇₅)

7.5 (6.0–9.4)

5.4 (4.6–6.5)

0.000

 Scr P₅₀ (P₂₅–P₇₅)

103 (67–153)

71 (61–82)

0.000

 UA P₅₀ (P₂₅–P₇₅)

464 (321–599)

325 (280–383)

0.000

 TG P₅₀ (P₂₅–P₇₅)

1.42 (1.04–2.43)

1.34 (0.97–1.96)

0.225

 TC P₅₀ (P₂₅–P₇₅)

4.20 (3.35–5.11)

4.21 (3.43–4.97)

0.616

 HDL-C P₅₀ (P₂₅–P₇₅)

1.11 (0.96–1.39)

1.12 (0.95–1.31)

0.137

 LDL-C P₅₀ (P₂₅–P₇₅)

2.75 (2.33–3.22)

2.47 (1.91–3.13)

0.315

 HbA1C P₅₀ (P₂₅–P₇₅)

7.6 (6.5–8.7)

6.3 (5.7–7.5)

0.000